In the field of scientific and technological innovation, Unicornshell has garnered attention through its strength and innovation. On August 11, Liaoning Unicornshell Pharmaceutical Technology Co., Ltd. stood out in the 14th China Innovation and Entrepreneurship Competition, securing first place in the industry category with a high score of 92.22 points, demonstrating the vibrant momentum of Liaoning's biopharmaceutical industry.
A Barometer of Liaoning's Technological Innovation
This year's Liaoning Regional Competition was themed “Gathering Through Innovation, Embracing the New Together,” aiming to identify and nurture high-growth potential technology companies while driving industrial upgrading and the transition between old and new growth drivers. The competition spanned fields such as next-generation information technology, advanced equipment manufacturing, new materials, and biopharmaceuticals, with the entire evaluation process conducted openly, fairly, and impartially.
Unicornshell: Innovation-Driven, Industry Benchmark
Unicornshell is a technology-driven enterprise specializing in the research, development, production, and sales of pharmaceutical excipients. Its core products are plant-based hollow capsules, including the first-generation hydroxypropyl methylcellulose capsules and the second-generation hydroxypropyl starch capsules. With technology leading the industry by 3-5 years, the company holds over 30 domestic and international patents and has established a comprehensive intellectual property protection system.
Plant-based capsules represent an important development direction in the pharmaceutical sector, aligning with the national “14th Five-Year Plan” for high-quality pharmaceutical development and the encouraging policies outlined in the “Guidance Catalog for Industrial Structure Adjustment (2019 Edition)” regarding the research and development of new excipients. They fundamentally address the safety concerns associated with traditional gelatin capsules, driving the high-quality development of the pharmaceutical excipient industry. Quanjikang adheres to its mission of “promoting medication safety and safeguarding human health,” actively responds to national industrial policies and the rural revitalization strategy, and continuously drives industry innovation and upgrading.
Innovation-Driven, Empowering Industrial Upgrading
Winning first place is a testament to Unicornshell's strengths in R&D capabilities, technological achievements, and corporate management, and marks a significant step forward in the company's efforts to advance smart manufacturing and the application of green new materials. In the future, Unicornshell will continue to adhere to a dual-drive strategy of “technological innovation + market expansion,” deepen industry-academia-research collaboration, strengthen intellectual property protection, and build an internationally leading plant-based capsule industry system to contribute to the high-quality development of the biopharmaceutical industry in Liaoning Province and across China.
Future Outlook
As global demand for high-quality plant-based capsules continues to grow, Unicornshell will leverage the competition platform and policy opportunities to accelerate the implementation of more innovative projects, continuously empower the upgrading of the green pharmaceutical industry chain, and strive to become a global leader in the plant-based capsule industry.
